Healthcare Industry News: Dermal Filler
News Release - August 1, 2007
FzioMed Appoints Kevin Sidow to Board of DirectorsSAN LUIS OBISPO, Calif.--(HSMN NewsFeed)--FzioMed, Inc., a leader in surgical biomaterials, announced today the appointment of Kevin K. Sidow, former St. Francis Medical Technologies, Inc. President and CEO, to FzioMed's board of directors.
While at St. Francis Medical, Mr. Sidow was responsible for overall operations and the achievement of milestones such as FDA approval of the X Stop spinal decompression device and the acquisition of St. Francis by Kyphon, Inc. Previously, Mr. Sidow served as Worldwide President of J & J DePuy where he oversaw global operations of the company's orthopedic, spine, trauma and sports medicine businesses. He has over twenty years of experience in orthopedic and neurosurgical device industries and is recognized for his achievements in driving successful medical technology initiatives.
"We are very pleased to welcome Kevin to FzioMed's board," stated Ron Haynes, Chairman of FzioMed, Inc. "We look forward to having his experience as a medical device industry leader on hand as we grow the company."
John Krelle, FzioMed President and CEO said, "FzioMed is at an exciting stage of commercialization and Kevin's background in high-growth companies with pioneering spine surgery products is an excellent complement to our business."
Founded in 1996, FzioMed is a privately held medical company developing and commercializing absorbable, surgical biomaterials based on the company's patented science. FzioMed's innovative polymer technology has uses in a variety of specialties including orthopedics, spine, gynecology, general surgery and aesthetic surgery. FzioMed products include Oxiplex/SP, the leading adhesion barrier gel for spine surgery, and Laresse(TM) cosmetic Dermal Filler, both currently marketed outside of the U.S. Go to www.fziomed.com
FzioMed®, Oxiplex® and Laresse(TM) are trademarks of FzioMed, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.